David A. Savitsky

3.3k total citations · 2 hit papers
28 papers, 2.6k citations indexed

About

David A. Savitsky is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, David A. Savitsky has authored 28 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Immunology, 14 papers in Oncology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in David A. Savitsky's work include Immune Cell Function and Interaction (10 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and CAR-T cell therapy research (9 papers). David A. Savitsky is often cited by papers focused on Immune Cell Function and Interaction (10 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and CAR-T cell therapy research (9 papers). David A. Savitsky collaborates with scholars based in United States, Japan and Czechia. David A. Savitsky's co-authors include Tomohiko Tamura, Tadatsugu Taniguchi, Hideyuki Yanai, Kathryn Calame, Kenya Honda, Hideo Negishi, Tatsuma Ban, Shizuo Akira, Sho Hangai and Ryuji Koshiba and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Journal of Experimental Medicine.

In The Last Decade

David A. Savitsky

25 papers receiving 2.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The IRF Family Transcription Factors in Immunity and Oncogenesis

2008 1.0k citations Tomohiko Tamura, Hideyuki Yanai et al. Annual Review of Immunology profile →
HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses

2009 548 citations Hideyuki Yanai, Tatsuma Ban et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Savitsky United States	12	1.8k	788	588	288	267	28	2.6k
Sinéad E. Keating Ireland	15	2.1k 1.2×	1.0k 1.3×	551 0.9×	308 1.1×	536 2.0×	18	2.7k
Tori C. Freitas United States	14	1.9k 1.1×	956 1.2×	439 0.7×	414 1.4×	351 1.3×	17	3.1k
Shyr‐Te Ju United States	28	2.0k 1.1×	1.2k 1.5×	323 0.5×	315 1.1×	248 0.9×	75	3.2k
Kisato Nosaka Japan	26	2.1k 1.2×	643 0.8×	457 0.8×	167 0.6×	164 0.6×	89	3.0k
Wing Y. Lam United States	12	2.2k 1.2×	1.1k 1.3×	338 0.6×	480 1.7×	478 1.8×	13	3.2k
Karen Toy United States	16	1.1k 0.6×	890 1.1×	752 1.3×	189 0.7×	245 0.9×	18	2.6k
Soo Young Yang United States	31	4.4k 2.4×	877 1.1×	827 1.4×	170 0.6×	348 1.3×	90	5.4k
Ana M. Gamero United States	30	1.8k 1.0×	958 1.2×	856 1.5×	267 0.9×	337 1.3×	59	2.8k
Sabine M. Lang United States	18	1.2k 0.7×	1.1k 1.4×	249 0.4×	130 0.5×	592 2.2×	25	2.5k
Junji Nishida Japan	24	642 0.4×	1.0k 1.3×	539 0.9×	151 0.5×	212 0.8×	78	2.4k

Countries citing papers authored by David A. Savitsky

Since Specialization

Citations

This map shows the geographic impact of David A. Savitsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Savitsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Savitsky more than expected).

Fields of papers citing papers by David A. Savitsky

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Savitsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Savitsky. The network helps show where David A. Savitsky may publish in the future.

Co-authorship network of co-authors of David A. Savitsky

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Savitsky. A scholar is included among the top collaborators of David A. Savitsky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Savitsky. David A. Savitsky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ward, Rebecca, Benjamin Morin, Beth G. Wensley, et al.. (2024). Abstract 3915: BMS-986442 (AGEN1777), a novel TIGIT/CD96 bispecific antibody, demonstrates superior monotherapy and combination activity versus conventional anti-TIGIT antibodies in preclinical models. Cancer Research. 84(6_Supplement). 3915–3915.

Tanne, Antoine, C Galand, Abdo Abou-Slaybi, et al.. (2021). Abstract 1878: Fc-enhanced anti-CTLA-4 antibody, AGEN1181: new mechanistic insights for potent antitumor immunity and combination potential in treatment-resistant solid tumors. Cancer Research. 81(13_Supplement). 1878–1878. 1 indexed citations

Galand, C, James Strauss, Richard D. Carvajal, et al.. (2020). 377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects. SHILAP Revista de lepidopterología. A229.2–A230. 6 indexed citations

Galand, C, Yanping Xiao, Cornelia Mundt, et al.. (2019). AGEN2373 is a conditionally-active agonist antibody targeting the costimulatory receptor CD137 for the treatment of human malignancies.. Journal of Clinical Oncology. 37(15_suppl). e14005–e14005.

Waight, Jeremy D., Mariana Manrique, Priyadarshini Iyer, et al.. (2019). Preclinical functional characterization of AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody for the treatment of patients with early and advanced malignancies.. Journal of Clinical Oncology. 37(15_suppl). e14126–e14126. 1 indexed citations

Chand, Dhan, Jeremy D. Waight, Nicholas S. Wilson, et al.. (2019). Abstract 2390: FcgR co-engagement by anti-TIGIT monoclonal antibodies enhances T cell functionality and antitumor immune responses. Cancer Research. 79(13_Supplement). 2390–2390. 3 indexed citations

Waight, Jeremy D., Dhan Chand, Thomas Horn, et al.. (2018). Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. Cancer Cell. 33(6). 1033–1047.e5. 64 indexed citations

Savitsky, David A., Rebecca Ward, Cornelia Mundt, et al.. (2018). Abstract 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies. Cancer Research. 78(13_Supplement). 3819–3819. 22 indexed citations

Coward, Jermaine, Charlotte Lemech, Tarek Meniawy, et al.. (2018). Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors. Annals of Oncology. 29. viii417–viii417. 3 indexed citations

10.

González-Castro, Ana María, Mariana Manrique, Ekaterina Breous, et al.. (2016). Abstract 3204: INCAGN01949: an anti-OX40 agonist antibody with the potential to enhance tumor-specific T-cell responsiveness, while selectively depleting intratumoral regulatory T cells. Cancer Research. 76(14_Supplement). 3204–3204. 4 indexed citations

11.

Savitsky, David A., Hideyuki Yanai, Tomohiko Tamura, Tadatsugu Taniguchi, & Kenya Honda. (2010). Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Proceedings of the National Academy of Sciences. 107(22). 10154–10159. 77 indexed citations

12.

Savitsky, David A., Tomohiko Tamura, Hideyuki Yanai, & Tadatsugu Taniguchi. (2010). Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunology Immunotherapy. 59(4). 489–510. 240 indexed citations

13.

Lord, Christopher A., David A. Savitsky, Raquel Sitcheran, et al.. (2009). Blimp-1/PRDM1 Mediates Transcriptional Suppression of the NLR Gene NLRP12/Monarch-1. The Journal of Immunology. 182(5). 2948–2958. 26 indexed citations

14.

Yanai, Hideyuki, David A. Savitsky, Tomohiko Tamura, & Tadatsugu Taniguchi. (2009). Regulation of the cytosolic DNA-sensing system in innate immunity: a current view. Current Opinion in Immunology. 21(1). 17–22. 51 indexed citations

15.

Yanai, Hideyuki, Tatsuma Ban, Zhichao Wang, et al.. (2009). HMGB proteins function as universal sentinels for nucleic-acid-mediated innate immune responses. Nature. 462(7269). 99–103. 548 indexed citations breakdown →

16.

Tamura, Tomohiko, Hideyuki Yanai, David A. Savitsky, & Tadatsugu Taniguchi. (2008). The IRF Family Transcription Factors in Immunity and Oncogenesis. Annual Review of Immunology. 26(1). 535–584. 1011 indexed citations breakdown →

17.

Magnúsdóttir, Erna, Sergey Kalachikov, Koji Mizukoshi, et al.. (2007). Epidermal terminal differentiation depends on B lymphocyte-induced maturation protein-1. Proceedings of the National Academy of Sciences. 104(38). 14988–14993. 127 indexed citations

18.

Savitsky, David A., Luisa Cimmino, Tracy C. Kuo, Gislâine A. Martins, & Kathryn Calame. (2007). Multiple Roles for Blimp-1 in B and T Lymphocytes. Advances in experimental medicine and biology. 596. 9–30. 10 indexed citations

19.

Shelef, Miriam A., Kuo‐I Lin, David A. Savitsky, Jerry Liao, & Kathryn Calame. (2005). Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. The Journal of Experimental Medicine. 202(11). 1471–1476. 178 indexed citations

20.

Savitsky, David A.. (1984). A Publisher's Guidelines for Educational Software Development.. Educational Technology archive. 24(4). 45.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact